Showing 2801-2810 of 5685 results for "".
- LIGHTMED Appoints Lee Walker-Roberts as Global Business Development Directorhttps://modernod.com/news/lightmed-appoints-lee-walker-roberts-as-global-business-development-director/2476484/LIGHTMED announced the appointment of Lee Walker-Roberts as Global Business Development Director, effective immediately. Mr. Walker-Roberts is an experienced leader and executive advisor for high-tech companies ranging from privately-owned start-ups to companies with over $200 million in annual s
- US Military Develops Mobile Application to Treat Eye Injurieshttps://modernod.com/news/us-military-develops-mobile-application-to-treat-eye-injuries/2476479/The U.S. military medical researchers are developing a mobile application to connect combat medics with on-call ophthalmologists either in-theater or at a clinic to treat eye injuries of soldiers in the field, according to a
- Fraunhofer IAP Developing Contact lenses With Medicine and Sugarhttps://modernod.com/news/fraunhofer-iap-developing-contact-lenses-with-medicine-and-sugar/2476476/Researchers at the Fraunhofer Institute for Applied Polymer Research IAP are working with Israeli and German partners to develop long-wearing contact lenses that can release medicine. The active ingredient is encapsulated in liposomes and bound to the inside of the contact lenses. This enables it
- NovaBay Pharmaceuticals Announces New Partner Pharmacy Programhttps://modernod.com/news/novabay-pharmaceuticals-announces-new-partner-pharmacy-program/2476465/NovaBay Pharmaceuticals announced a new pharmacy partnering program in an effort to ensure all patients in the United States have reliable and affordable access to prescription Avenova, according to a company news release. NovaBay has recently added six new pharmacies as Avenova channel partners.
- Avedro’s Corneal Cross-Linking Procedure Now Covered by 65 Coverage Policieshttps://modernod.com/news/avedros-corneal-cross-linking-procedure-now-covered-by-65-coverage-policies/2476444/Avedro announced that four new providers—Providence Health Plan in the Pacific Northwest, Health New England, HealthPartners Minnesota, and Public Employees Health Plan (PEHP) in Utah—have issued positive coverage pol
- NovaBay Pharmaceuticals Announces Investments of $5 Million to Support US Avenova Commercialization Strategyhttps://modernod.com/news/novabay-pharmaceuticals-announces-investments-of-5-million-to-support-us-avenova-commercialization-strategy/2476424/NovaBay Pharmaceuticals announced investments totaling $5 million to support the recent strategic shift in its US commercialization strategy aimed at driving growth in Avenova sales while maintaining cost effectiveness. The investments include a convertible loan of $2 million from Ascendia
- FDA Prepares for Possible Device Shortages After Gas Leaks Lead to Closure of Sterilization Planthttps://modernod.com/news/fda-prepares-for-possible-device-shortages-after-gas-leaks-lead-to-closure-of-sterilization-plant/2479583/The FDA is working to prevent potential shortages of medical devices after the closure of an Illinois sterilization plant, which was due to a state environmental protection order, according to a
- IOT Introduces EVOlens Machine Learning System Designed to Increase Patient Satisfaction Over Timehttps://modernod.com/news/iot-introduces-evolens-machine-learning-system-designed-to-increase-patient-satisfaction-over-time/2479585/Indizen Optical Technologies (IOT) has introduced the EVOlens, a recommendation system that objectively chooses the best progressive design for each patient based on the feedback of wearers with similar visual profile
- I-PEN Osmolarity System Now Available in Brazil Through Partnership with DryComhttps://modernod.com/news/i-pen-osmolarity-system-now-available-in-brazil-through-partnership-with-drycom/2476420/The I-PEN is the world’s first, point-of-care, electronic diagnostic testing device to detect and indirectly measure the tear film osmolarity levels associated with marginal, mild, moderate and severe dry eye disease. The I-PEN Osmolarity System, used in conjunction with the I-PEN Osmolarity Sing
- RegeneRx and Lee’s Pharm to Accelerate RGN-259 Development in Chinahttps://modernod.com/news/regenerx-and-lees-pharm-to-accelerate-rgn-259-development-in-china/2476417/RegeneRx Biopharmaceuticals and Lee’s Pharmaceutical Holdings, a Hong Kong-based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications. Lee’s Pharm previously licensed RGN-2